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Validation of the 4B5 rabbit monoclonal
antibody in determining Her2/neu status in
breast cancer
Bert van der Vegt1, Geertruida H de Bock2, Joost Bart1, Nick G Zwartjes1
and Jelle Wesseling1,3
1Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The
Netherlands; 2Department of Epidemiology, University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands and 3Department of Pathology, Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, The Netherlands
HER2 overexpression in breast cancer is associated with worse clinical outcome. To select patients for anti-
Her2-based therapy immunohistochemistry is commonly performed as a first step to assess Her2 status.
However, interobserver and interlaboratory variability can significantly compromise adequate assessment of
Her2 status. In addition, immunohistochemistry does not always result in an unambiguous test result requiring
additional testing for Her2 gene amplification. This study aimed to improve the reliability of Her2
immunohistochemistry by using rabbit monoclonal antibody 4B5 as an alternative to mouse monoclonal
antibody CB11 routinely used in our laboratory. Therefore, 283 breast adenocarcinomas were included in a
tissue microarray. Immunohistochemistry using the 4B5 and CB11 antibodies, and fluorescence and
chromogenic in situ hybridization (FISH or CISH) were performed. Immunohistochemistry was scored by two
independent investigators. We found that 4B5 staining was more distinct than CB11 staining. For CB11
staining, there were 12% (BV) and 5% (JW) 2þ scores compared with 4% (BV) and 2% (JW) for 4B5. There was a
strong trend towards higher interobserver agreement for 4B5 compared with CB11 (4B5: j 0.87, 95% CI 0.79–
0.96; CB11: j 0.77, 95% CI 0.66–0.88). There were no significant differences in sensitivity, specificity and
predictive values between CB11 and 4B5. Our results indicate that the 4B5 antibody provides more robust
assessment of immunohistochemical Her2/neu status and will reduce the number of gene amplification tests
compared with CB11. However, for tumours with a 2þ score additional gene amplification measurement using
FISH or CISH remains necessary.
Modern Pathology (2009) 22, 879–886; doi:10.1038/modpathol.2009.37; published online 20 March 2009
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The status of the Her2 receptor is an important factor
in the prognosis and treatment choice in primary
breast carcinoma.1 Mortality and recurrence are
reduced in patients with Her2/neu-positive breast
carcinoma that receive adjuvant therapy with both
the humanized anti-Her2/neu monoclonal antibody
therapy trastuzumab and chemotherapy.2–5
Trastuzumab therapy, however is associated with
cardiotoxicity, in 2–4.7% of patients when used
as monotherapy, but in up to 27% when given
concomitantly with anthracycline and cyclophos-
famide therapy.6 Therefore, this treatment is only
given to patients with confirmed Her2/neu-positive
breast carcinoma and adequate left ventricle ejection
fraction. Several methods are used to assess Her2/
neu status in breast cancer. Measurement of gene
amplification using fluorescence in situ hybridiza-
tion (FISH) or chromogenic in situ hybridization
(CISH) is considered to be the ‘gold standard’ in the
assessment of Her2/neu status.7–9 However, the most
commonly used first-line method to determine
Her2/neu status is immunohistochemistry. Immu-
nohistochemistry is relatively inexpensive and a
routinely used technique in pathology laboratories,
which makes it easy to implement. Immunohisto-
chemistry results in a Her2/neu score ranging from
0 (no expression) to 3þ (strong complete tumour
cell membrane expression).10 This semiquantitative
scoring system does not always result in a clear
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positive or negative Her2/neu amplification status.
It is generally agreed that when a Her2 score is
ambiguous (2þ score) a gene amplification mea-
surement has to be performed.7,11,12 Another setback
of Her2 immunohistochemistry is the significant
interobserver variation and poor interlaboratory
reproducibility.13–16 As accurate diagnostic assess-
ment of HER2/neu is essential for the appropriate
application of trastuzumab-containing treatment
regiments, the concordance between immunohisto-
chemistry and the ‘gold standard’ gene amplifica-
tion assessment needs to be as high as possible.
Therefore, immunohistochemistry staining should
be improved to optimize accurate estimation of the
HER2/neu status.
In recent years, rabbit monoclonal antibodies have
been developed, which show higher affinity and
specificity than mouse monoclonal or rabbit poly-
clonal antibodies resulting in more reliable staining
results.17,18 To improve Her2 immunohistochemistry
reliability in our laboratory, we tested the potential
of the rabbit monoclonal antibody 4B5 directed
against Her2/neu as an alternative to the mouse
monoclonal CB11 directed against Her2/neu, using




To determine the size of the series, a power analysis
was performed. In this power analysis, we consid-
ered HER2/neu immunohistochemistry negative if
the staining pattern and intensity is equivalent to
score ‘0’ or ‘1þ ’ and positive if it is equivalent to
score ‘3þ ’. 2þ cases are not taken into account in
this power analysis, because they are clinically
uninformative. We assumed 10% 2þ cases. We also
assumed that the rabbit monoclonal antibody has a
better sensitivity and specificity than the mouse
monoclonal antibody CB11. Furthermore, a loss of
20% cases because of unavailability of tumour
material or uninterpretability of one or more of the
stainings was assumed. On the basis of these
assumptions, a sample size of 280 was required to
achieve 90% power to detect an odds ratio of 3.000
using a two-sided McNemar test with a significance
level of 0.05000. The odds ratio is equivalent to a
difference between two paired proportions of 0.100,
which occurs when the proportion TN negative vs
TO positive is 0.150 and the proportion TN positive
vs TO negative is 0.050. A total of 283 consecutive
female patients treated for a primary operable
invasive carcinoma of the breast at the University
Medical Center Groningen between January 2002
and December 2005 were included in this study.
Afterwards eight patients were excluded because no
representative material was available in the tissue
microarray blocks. The analyses have been per-
formed on the resulting group of 275 patients.
Patient and tumour characteristics were obtained
retrospectively from hospital records and are sum-
marized in Table 1.
Tissue Microarray Construction
From the patient’s tumour paraffin block, three
0.6 mm core samples of the most representative
tumour area were included in a tissue microarray.
The technique of tissue microarray production has
been described and validated for breast carcinoma
by others.19,20 In the latter study, authors showed
that the concordance between the tissue microarray
with the whole tissue sections was over 97% if three
0.6 mm core samples per tumour were included in
the TMA. In brief, tissue microarrays were compiled
as follows: the most representative tumour area
was marked on the original haematoxylin and eosin
(H&E)-stained section. Using this section as an
orientation, three 0.6 mm core punches were taken
from the selected area in the donor blocks and
mounted in a recipient block, using a manual tissue
microarray device (Beecher Instruments, Silver
Springs, MD, USA). In total, seven tissue microarray
blocks, each containing tumour cores from 40 to 50
patients, were made. Using a standard microtome,
3mm sections were cut from these tissue microarray
blocks.
Immunohistochemistry, FISH and CISH
Immunohistochemistry for rabbit monoclonal anti-
body 4B5 (PATHWAYs HER-2/neu (4B5) rabbit
Table 1 Patient and tumour characteristics
n (%)
Age at diagnosis




Pathological tumour size (mm)
Median (range) 22 (1–140)
Pathological tumour type
IDC 109 (40)
IDC and DCIS 110 (40)
ILC 25 (9)
ILC and LCIS 6 (2)
other 25 (9)




n, number of cases; IDC, invasive ductal carcinoma; DCIS, ductal
carcinoma in situ; ILC, invasive lobular carcinoma; LCIS, lobular
carcinoma in situ; other, other specific subtypes of invasive breast
carcinoma.
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monoclonal antibody, Ventana Medical Systems,
Illkirch, Cedex, France) and mouse monoclonal
antibody CB11 (PATHWAY HER-2/neu (CB11)
mouse monoclonal antibody, Ventana Medical Sys-
tems) was performed on the tissue microarray
sections using the automated Benchmarks platform
(Ventana Medical Systems) and according to the
manufacturers recommendations. FISH (PathVysion
HER-2 DNA Probe Kit, Vysis Inc., Downers Grove,
IL, USA) and CISH (SPoT-Lights HER2 CISHt Kit,
Zymed, Carlsbad, CA, USA) assays were performed
according the manufacturers recommendations.
Evaluation of Immunohistochemistry, FISH and CISH
Scoring of the CB11 and 4B5 immunohistochemistry
stainings was performed independently by an
experienced pathologist (JW) and a senior resident
(BV). Her-2/neu expression was graded as recom-
mended by the HercepTestTM scoring guidelines: 0:
no staining at all or membrane staining in o10%
of the tumour cells; 1þ : a faint/barely perceptible
partial membrane staining in 410% of the tumour
cells; 2þ : weak-to-moderate complete membrane
staining in 410% of the tumour cells; 3þ : strong
complete membrane staining in 410%.
Fluorescence in situ hybridization was scored
according to the ASCO guidelines: the ratio of 20
cells was calculated. A ratio o1.8 was considered
negative, a ratio 42.2 was considered positive. For
the equivocal cases another 20 cells were counted.
In these cases, a ratio 2 was considered positive. A
ratio o2 was considered negative. For CISH,
tumours with at least five signals in more than
50% of the tumour cells were considered positive.
Data Analysis
All statistical analyses were performed using the
SPSS 14.0 software package.
The feasibility of both staining methods was
compared. The number of informative test results
and the number of 2þ scores were calculated for
each of the staining methods. Agreement between
immunohistochemistry results and in situ hybridi-
zation results were calculated in a cross tabulation
using a Pearson w2-test. Sensitivity and specificity
were calculated using two methods, including and
excluding 2þ scores. In the first method, 2þ scores
were considered a positive test result. This method
is most commonly used in literature and was
performed to compare our results to those found in
other studies. 2þ scores are, however, clinically
uninformative and were therefore eliminated from
analysis in the second method. The positive pre-
dictive value (PPV) was calculated by dividing the
number of cases in the immunohistochemistry 3þ
group with amplification on FISH or CISH by the
total number of cases with an immunohistochem-
istry 3þ score. The negative predictive value (NPV)
was calculated by dividing the number of cases
immunohistochemistry score 0 or 1þ without
amplification on FISH or CISH by the total number
of patients with an immunohistochemistry 0 or
1þ score. For sensitivity, specificity and predictive
values a 95% CI interval was calculated. Interobser-




In Figure 1, an example of both a 4B5 and a CB11
staining for 1 case is shown. In general, the 4B5
staining was more distinct compared with the
CB11 staining. Also the 4B5 staining showed less
nonspecific cytoplasmic staining.
Test Characteristics
Of the 275 cases included, 262 (95%) of the cases
were adequately represented in the tissue micro-
Figure 1 Comparison of 3þ case for 4B5 and CB11. (a) 4B5.
(b) CB11.
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array. Immunohistochemistry could be evaluated in
83 (JW) and 90% (BV) of the cases for 4B5, in 87 (JW)
and 91% (BV) of the cases for CB11. Differences in
evaluation percentages between authors have been
caused by disagreement on the overall percentage
of tumour available in the core punches and the
relative percentages of invasive tumour vs in situ
tumour available in the core punches. FISH could be
evaluated in 90% and CISH in 92% of the cases.
Agreement
In 230 of the 240 assessable cases (96%), there was
agreement between FISH and CISH scoring (k 0.837,
95% CI 0.737–0.937). There was an agreement of
80 (BV) and 81% (JW) between the scoring results of
4B5 and CB11 (Table 2). The disagreement between
scores is mainly caused by the 2þ scores. There was
a reduction of more than 50% for the number of
cases scored as 2þ when comparing CB11 with 4B5,
respectively, 28 cases (12%) vs 13 cases (4%) (BV)
and 12 cases (5%) vs 5 cases (2%) (JW). When exclu-
ding the 2þ cases from analysis, there was no
difference between both antibodies for the classi-
fication of cases as amplified or not amplified
(McNemar’s test P¼ 1.0, data not shown) eg, there
would be no clinical consequences when using
either of the antibodies. In Tables 3 and 4, the
results for the concordance between immunohisto-
chemistry and respectively FISH and CISH are
shown. Sensitivity (including and excluding
2þ scores), specificity (including and excluding
2þ scores), PPV and NPV of 4B5 and CB11 using
Table 2 Correlation of 4B5 and CB11 for observer BV (a) and JW (b)
(a)
CB11 BV
4B5 BV 0 1 2 3 Total
0 149 (95) 20 (50) 4 (14) 0 (0) 173 (71)
1 7 (4) 19 (48) 14 (50) 0 (0) 40 (16)
2 1 (1) 1 (2) 8 (29) 0 (0) 13 (4)
3 0 (0) 0 (0) 2 (7) 19 (100) 21(9)




4B5 JW 0 1 2 3 Total
0 106 (96) 28 (35) 0 (0) 0 (0) 134 (60)
1 5 (4) 51 (64) 6 (50) 0 (0) 62 (28)
2 0 (0) 1 (1) 4 (33) 0 (0) 5 (2)
3 0 (0) 0 (0) 2 (17) 20 (100) 22 (10)
Total 111 (100) 80 (100) 12 (100) 20 (100) 223 (100)
w2: Pr0.001
CB11: mouse monoclonal antibody CB11; 4B5: rabbit monoclonal antibody 4B5; BvdV: Bert van der Vegt; JW: Jelle Wesseling.
Table 3 comparison of immunohistochemistry with FISH
Amplification No amplification Total
IHC CB11 BvdV
0 3 (8) 150 (74) 153 (64)
1 2 (5) 38 (19) 40 (16)
2 13 (35) 15 (7) 28 (12)
3 19 (52) 0 (0) 19 (8)
Total 37 (100) 203 (100) 240 (100)
w2: Pr0.001
IHC 4B5 BvdV
0 5 (14) 165 (81) 170 (71)
1 4 (11) 36 (18) 40 (17)
2 7 (19) 3 (1) 10 (4)
3 21 (56) 0 (0) 21 (8)
Total 37 (100) 204 (100) 241 (100)
w2: Pr0.001
IHC CB11 JW
0 2 (5) 116 (59) 118 (51)
1 5 (14) 78 (40) 83 (36)
2 10 (27) 2 (1) 12 (5)
3 20 (54) 0 (0) 20 (8)
Total 37 (100) 196 (100) 233 (100)
w2: Pr0.001
IHC 4B5 JW
0 3 (8) 131 (69) 134 (60)
1 7 (20) 57 (30) 64 (28)
2 4 (11) 1 (1) 5 (2)
3 22 (61) 0 (0) 22 (10)
Total 36 (100) 189 (100) 225 (100)
w2: Pr0.001
IHC: immunohistochemistry; CB11: mouse monoclonal antibody
CB11; 4B5: rabbit monoclonal antibody 4b5; BvdV: Bert van der Vegt;
JW: Jelle Wesseling.
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both FISH and CISH as reference are shown in
Table 5. Sensitivity, specificity, PPV and NPV did
not show any significant differences between both
antibodies and between both observers. However,
there was a near significant difference in specificity
(including 2þ scores) for the lesser experienced
observer (BV) between 4B5 and CB11: (4B5: 0.99,
95% CI 0.95–1.0; CB11: 0.93, 95% CI 0.88–0.96).
Although not significant, there was a trend towards
an increased concordance between observers for 4B5
compared with CB11 (4B5: k 0.87, 95% CI 0.79–0.96;
CB11: k 0.77, 95% CI 0.66–0.88) (Table 6).
Discussion
In this study, we tested the potential of the 4B5 anti-
Her2 rabbit monoclonal antibody by comparing
it with the CB11 anti-Her2 mouse monoclonal anti-
body on a consecutive series of invasive breast
adenocarcinomas, using both FISH and CISH as
reference. We found that 4B5 staining was more
distinct and showed less nonspecific cytoplasmic
background staining, which led to a more than
50% reduction of the number of 2þ scores for 4B5
compared with CB11. In this well powered study
we found no significant differences in sensitivity,
specificity, predictive values and interobserver con-
cordance between 4B5 and CB11. However, there
was a trend towards a higher specificity for 4B5 for
one of the observers (BV) and a trend towards an
increased interobserver concordance for 4B5. The
– nonsignificant – differences in the test results of
Table 4 comparison of immunohistochemistry with CISH
Amplification No amplification Total
IHC CB11 BvdV
0 2 (6) 156 (76) 158 (65)
1 4 (11) 35 (17) 39 (16)
2 11 (31) 15 (7) 26 (11)
3 19 (52) 0 (0) 19 (8)
Total 36 (100) 206 (100) 242 (100)
w2: Pr0.001
IHC 4B5 BvdV
0 3 (8) 171 (83) 174 (71)
1 6 (17) 33 (16) 39 (16)
2 6 (17) 3 (1) 9 (4)
3 21 (58) 0 (0) 21 (9)
Total 36 (100) 207 (100) 243 (100)
w2: Pr0.001
IHC CB11 JW
0 1 (3) 121 (61) 122 (52)
1 6 (17) 74 (37) 80 (34)
2 9 (25) 3 (2) 12 (5)
3 20 (55) 0 (0) 20 (9)
Total 36 (100) 198 (100) 234 (100)
w2: Pr0.001
IHC 4B5 JW
0 2 (6) 134 (71) 136 (60)
1 9 (25) 53 (28) 62 (28)
2 3 (8) 2 (1) 5 (2)
3 22 (61) 0 (0) 22 (10)
Total 36 (100) 189 (100) 225 (100)
w2: Pr0.001
4B5, rabbit monoclonal antibody 4B5; BvdV, Bert van der Vegt; CB11,
mouse monoclonal antibody CB11; IHC, immunohistochemistry; JW,
Jelle Wesseling.






PPV NPV % 2+
4B5 BvdV 0.75 (0.57–0.87) 0.99 (0.95–1.0) 0.70 (0.50–0.85) 1.0 (0.98–1.0) 1.0 (0.81–1.0) 0.96 (0.92–0.98) 4
CB11 BvdV 0.83 (0.67–0.93) 0.93 (0.88–0.96) 0.79 (0.57–0.92) 1.0 (0.98–1.0) 1.0 (0.79–1.0) 0.97 (0.94–0.99) 12
4B5 JW 0.69 (0.52–0.83) 0.99 (0.96–1.0) 0.69 (0.50–0.83) 1.0 (0.98–1.0) 1.0 (0.82–1.0) 0.95 (0.91–0.97) 2






PPV NPV % 2+
4B5 BvdV 0.76 (0.58–0.88) 0.99 (0.95–1.0) 0.70 (0.50–0.85) 1.0 (0.98–1.0) 1.0 (0.81–1.0) 0.96 (0.92–0.98) 4
CB11 BvdV 0.86 (0.70–0.95) 0.93 (0.88–0.96) 0.76 (0.54–0.90) 1.0 (0.98–1.0) 1.0 (0.80–1.0) 0.97 (0.93–0.99) 11
4B5 JW 0.72 (0.55–0.85) 0.99 (0.96–1.0) 0.67 (0.48–0.81) 1.0 (0.97–1.0) 1.0 (0.82–1.0) 0.94 (0.90–0.97) 2
CB11 JW 0.81 (0.64–0.91) 0.99 (0.96–1.0) 0.74 (0.53–0.88) 1.0 (0.98–1.0) 1.0 (0.80–1.0) 0.97 (0.93–0.98) 5
4B5, rabbit monoclonal antibody 4b5; BvdV, Bert van der Vegt; CB11, mouse monoclonal antibody CB11; IHC, immunohistochemistry; JW, Jelle
Wesseling; NPV, negative predictive value; PPV, positive predictive value.
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both observers would have no consequences for
clinical decision making regarding the Her2 status of
the carcinomas investigated.
Gene amplification measurement is considered to
be the ‘gold standard’ for Her2/neu status assess-
ment,7–9 although it suffers from variability between
institutes21,22, and the sensitivity varies between
detection methods used.9 Traditionally, gene ampli-
fication measurement has been performed using
FISH assays for Her2/neu gene amplification. This
method, however, has several disadvantages: FISH
is expensive, is time demanding,8 is not readily
accommodated in most pathology laboratories and
is accompanied by technical challenges.23 More
recently CISH assays have been developed. Instead
of the fluorogens used in FISH, this technique uses
chromogens. This has several advantages24: where
FISH requires a fluorescence microscope for inter-
pretation, CISH can be interpreted using a normal
bright field microscope. CISH allows analysis of
tumour morphology, making it possible to interpret
tumour heterogeneity and gene copy number in
different components of the tumour (an invasive and
an in situ component). Also FISH signals are labile
and fade over time, but CISH produces a permanent
staining.
Many authors have compared CISH with FISH
(reviewed by Lambros et al24). Most studies find an
agreement of both methods of more than 90%. In a
multicenter study, where pathology laboratories
blindly performed CISH on cases from each other
this method was validated.25 That study also repor-
ted an intra- and interobserver agreement of over
90% and concluded that CISH is a viable alternative
to FISH. In this study, the agreement between
FISH and CISH was 96%, which is in line with
the conclusions of those earlier studies. Of the
10 discordant cases in our series 5 cases contained
an in situ component. This tumour heterogeneity
might have led to the discordance because distinc-
tion between the invasive and the in situ component
can be difficult in FISH where tumour morphology
is not readily recognized in all cases.
Most pathology laboratories use immuno-
histochemistry to assess Her2/neu status. Immuno-
histochemistry is not only less expensive than
in situ methods, there is also much experience with
immunohistochemistry, which makes it a method
that is easily implemented in the daily practice
of pathology laboratories. Immunohistochemistry,
however, has several disadvantages: immunohisto-
chemistry is scored semiquantitively, which leads to
a 0 – 3þ score rather than to a clear amplification/
no amplification outcome. Scores 0 and 1þ are
considered non-amplified and score 3þ is consid-
ered amplified. An ideal Her2 antibody has a low
number of indeterminate (2þ ) cases and a high PPV
and NPV. We found that 4B5 staining compared
with CB11 was more distinct and showed less
nonspecific cytoplasmic background staining. This
has led to an increase in interobserver concordance
(4B5: k 0.87, 95% CI 0.79–0.96; CB11: k 0.77, 95% CI
0.66–0.88) that showed a trend towards significance.
Interobserver concordance is essential because it has
far reaching consequences for the choice of therapy
regimen and response to therapy. A few studies have
assessed interobserver concordance for CB11. Two
of those studies found an interobserver concordance
of 0.74, which is comparable with our results
(0.77).13,15 In a study by Tsuda et al16 an interobser-
ver concordance of only 0.29 was found for CB11.
However, this study used a different method to
calculate concordance. The concordance of 0.87 that
we found for 4B5 is considered almost perfect,26
which underlines that 4B5 is a safe method to assess
Her2 status in breast cancer. To our knowledge, no
other studies have assessed interobserver concor-
dance for 4B5. Interlaboratory concordance was not
assessed in this study. One study mentions a perfect
interlaboratory concordance on a very limited
number of cases.27 Future studies are needed to
assess this issue.
In this series, a cutoff of 10% staining was used
for scoring Her2 immunohistochemistry. This cutoff
was chosen based on Dutch guidelines, which differ
from the ASCO guideline using a cutoff of 30%.
Table 7 Sensitivity, specificity, predictive and concordance for CB11 from literature
Author Study size Sensitivity Specificity Method PPV NPV
Kakar et al 30 112 0.93 (0.66–1.0)a 0.98 (0.90–1.0)a 2 0.88 (0.60–0.98)a 0.99 (0.92–1.0)a
Bartlett et al13 213 0.85 (0.70–0.94)a 0.69 (0.62–0.76)a 1 0.40 (0.30–0.51)a 0.95 (0.89–0.98)a
Press et al9 74 0.721 (0.56–0.85) 1.00 (0.95–1.0) 1
Press et al21 64 0.95 (0.74–1.0) 0.84 (0.70–0.93) 1
Ricardo et al31 190 0.52 (0.37–0.67)a 0.98 (0.93–1.0)a 2 0.92 (0.72–0.99)a 0.83 (0.75–0.89)a
Powell et al27 178b 0.92 (0.83–0.96)a 0.91 (0.82–0.96)a 1 0.92 (0.83–0.96)a 0.91 (0.82–0.96)a
144b 0.74 (0.64–0.83)a 0.91 (0.80–0.97)a 1 0.93 (0.83–0.97)a 0.71 (0.59–0.80)a
Egervari et al29 199 0.83 (0.58–0.96)a 0.99 (0.96–1.0)a 2 0.94 (0.68–1.0)a 0.98 (0.94–0.99)a
Method 1, 2+ and 3+ scores considered positive; Method 2, 2+ cases excluded from analysis; PPV, positive predictive value; NPV, negative
predictive value.
a
Calculated from the data available in the article.
b
Two separate subsets were studied in the article.
Her2 antibody 4B5 validation
B van der Vegt et al
884
Modern Pathology (2009) 22, 879–886
However, this difference in cutoff did not cause a
significant change in the results.
The number of cases that were scored as 2þ was
lower for 4B5. For 4B5, observers scored 4 and 2% 2
þ cases; for CB11 this was 12 and 5%. The number
of CB11 2þ cases in this study is comparable the
with numbers in literature, where the number of
cases scored 2þ using an mouse monoclonal anti-
body ranges from 2 to 20.5%, and is usually around
10%.28 We expect that the introduction of 4B5 will
reduce the number of FISH or CISH assays that will
have to be performed, which leads to a reduction in
costs. In this well powered study, this decrease of
indeterminate cases did not lead to a significant
difference in sensitivity, specificity, or predictive
power between CB11 and 4B5. Small numbers did
not allow a statistically reliable subgroup analysis to
assess differences in sensitivity, specificity and
predictive values for the immunohistochemistry
2þ cases of both antibodies using FISH or CISH as
a reference. In table 7, the results from other studies
assessing sensitivity, specificity and predictive
values of CB11 are shown. Most studies considered
2þ cases to be amplified for the calculations. As
discussed before 2þ cases correlate with gene
amplification very poorly.7,11,12 We believe that 2þ
cases should be excluded from analysis when
assessing sensitivity, specificity and predictive
values. The values for sensitivity, specificity and
predictive values that we found in this study are
comparable with those found in literature. Powell
et al27 performed a study comparing 4B5 with CB11
using FISH as a reference in two subsets of cases,
one containing samples from a single institution,
and one containing samples from a multicenter
tissue bank. In that study the levels of sensitivity
were higher and the levels of specificity were lower
than in this study. However, these differences were
not significant for the subset best comparable with
this study group, ie, the single institution subset.
PPV and NPV show no significant difference
between both antibodies, which underlines that
the lower number of indeterminate cases which
led to the increase in sensitivity and specificity did
not cause a loss of predictive value of the test. In a
group of 199 invasive breast cancers, Egervari et al29
compared the 4B5 antibody with a number of
antibodies including the CB11 antibody using FISH
as a reference. When recalculating their results
using the method described earlier they had sensi-
tivity (0.76 (0.5–0.92)), specificity (0.99 (0.96–1.0)),
PPV (0.93 (0.64–1.0)) and NPV (0.97 (0.93-0.99)) that
does not differ significantly to our results. Although
they suggest a lower sensitivity of 4B5 compared
with CB11, this result is not significant (Table 7).
In conclusion, we showed that the novel 4B5
rabbit monoclonal anti-Her2/neu antibody has a
good agreement with both FISH and CISH and has a
sensitivity, a specificity and predictive values com-
parable with CB11. We found a reduction of more
than 50% in the number of indeterminate cases for
4B5 and an increase in interobserver concordance.
Our results indicate that immunohistochemistry
using the 4B5 antibody provides more robust and
hence more reliable assessment of the Her2/neu
status detection and will reduce the number of
gene amplification tests compared with the CB11
antibody. However, for patients with a 2þ score
additional gene amplification measurement using
FISH or CISH remains mandatory.
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